Drugs / Lu AF90103
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05306366 | Mar → Jun 2022 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT04940949 | May → Nov 2021 | — | H. Lundbeck A/S | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lu AF90103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04940949 ↗ |
| Route | Intravenous | “Participants will receive a single IV dose of Lu AF90103.” NCT04940949 ↗ |